IMC-001 clinical trials
Also written IMC-001 and STI-3031.
How each study uses IMC-001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the IMC-001 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
ImmuneOncia Therapeutics Inc. (3) · Sorrento Therapeutics, Inc. (2) · Asan Medical Center (1) · Mayo Clinic (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test IMC-001.
- Jun 2027A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid TumorPhase 2 · ImmuneOncia Therapeutics Inc.
Studies
Open first, then newest update. How each study uses IMC-001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid TumorRecruitingPhase 2ImmuneOncia Therapeutics Inc.NCT06365840Written as IMC-001
- Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal CancersActive, not recruitingPhase 2Asan Medical CenterNCT04196465Written as IMC-001
- A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeActive, not recruitingPhase 2ImmuneOncia Therapeutics Inc.NCT04414163Written as IMC-001
- Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 StudyTerminatedPhase 1Mayo ClinicNCT05393713Written as Anti-PD-L1 Monoclonal Antibody IMC-001
- A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT03999658Written as STI-3031
- Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid TumorsWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04809012Written as STI-3031
- Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid TumorsCompletedPhase 1ImmuneOncia Therapeutics Inc.NCT03644056Written as IMC-001
Codes
What other systems call IMC-001 · ClinicalTrials.gg INT001912
- MeSH (NLM) C000722928IMC-001One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722928 | IMC-001 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.